Related references
Note: Only part of the references are listed.Structure-function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk
Christina Gkolfinopoulou et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
C. Michael Gibson et al.
AMERICAN HEART JOURNAL (2021)
Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention
Pei Zhu et al.
PLATELETS (2021)
Higher oxidized high-density lipoprotein to apolipoprotein A-I ratio is associated with high-risk coronary plaque characteristics determined by CT angiography
Kazuki Suruga et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)
Denaturation of human plasma high-density lipoproteins by urea studied by apolipoprotein A-I dissociation
Alexander D. Dergunov et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2021)
The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study
Ji Eun Jun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia
Leopoldo Perez de Isla et al.
EUROPEAN HEART JOURNAL (2021)
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
Ismael Valladolid-Acebes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017
Maedeh Amini et al.
BMC PUBLIC HEALTH (2021)
Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study
Markus Arnold et al.
EUROPEAN HEART JOURNAL (2021)
Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors
Kwok Leung Ong et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Genome-Wide Association Study and Identification of a Protective Missense Variant on Lipoprotein(a) Concentration Protective Missense Variant on Lipoprotein(a) Concentration-Brief Report
M. Abdullah Said et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)
Myeloperoxidase Targets Apolipoprotein A-I for Site-Specific Tyrosine Chlorination in Atherosclerotic Lesions and Generates Dysfunctional High-Density Lipoprotein
Zelong Jin et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2021)
HDL Containing Apolipoprotein C-III is Associated with Insulin Sensitivity: A Multicenter Cohort Study
Rain Yamamoto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Ioanna Gouni-Berthold et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
Fabrizia Bonacina et al.
CELLS (2021)
Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag
Bridget M. Kuehn
CIRCULATION (2021)
Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study
Capucine Bertrand et al.
DIABETOLOGIA (2021)
Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study
Markus Arnold et al.
EUROPEAN HEART JOURNAL (2021)
Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia
Leopoldo Perez de Isla et al.
EUROPEAN HEART JOURNAL (2021)
Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Clinical review on triglycerides
Ulrich Laufs et al.
EUROPEAN HEART JOURNAL (2020)
Statins and increases in Lp(a): an inconvenient truth that needs attention
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study
Massimiliano Ruscica et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease
Raul Fernandez-Prado et al.
CLINICAL KIDNEY JOURNAL (2020)
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
Federica Fogacci et al.
CURRENT ATHEROSCLEROSIS REPORTS (2020)
Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies
Arrigo F. G. Cicero et al.
DRUG SAFETY (2020)
Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a)
Claudia Stefanutti et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia
Laura D'Erasmo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
Maciej Banach et al.
JAMA CARDIOLOGY (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression?
Andrea Bonnin Marquez et al.
BIOMEDICINES (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Biological Consequences of Dysfunctional HDL
Angela Pirillo et al.
CURRENT MEDICINAL CHEMISTRY (2019)
A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
Ye-Xuan Cao et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2019)
High-Density Lipoprotein Function and Dysfunction in Health and Disease
Scott T. Chiesa et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J. Alexander et al.
EUROPEAN HEART JOURNAL (2019)
An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients
Marcelino Bermudez-Lopez et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P. Wilson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice
Thomas M. Stulnig et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
Current and future role of lipoprotein(a) in preventive cardiology
Adam N. Berman et al.
CURRENT OPINION IN CARDIOLOGY (2019)
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
Hayato Tada et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2019)
Lp(a): Addressing a Target for Cardiovascular Disease Prevention
Nestor Vasquez et al.
CURRENT CARDIOLOGY REPORTS (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Severe hypertriglyceridemia is primarily polygenic
Jacqueline S. Dron et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis
Haris Riaz et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2019)
Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study
Christian M. Madsen et al.
EUROPEAN HEART JOURNAL (2018)
Lipoprotein(a): A missing culprit in the management of athero-thrombosis?
Gianna Ferretti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease
Rai Ajit K. Srivastava
MOLECULAR AND CELLULAR BIOCHEMISTRY (2018)
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
Shipra Agrawal et al.
NATURE REVIEWS NEPHROLOGY (2018)
APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137895 Individuals
Anders B. Wulff et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes
Priska Stahel et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
High-density Lipoprotein (HDL) Dysfunction and the Future of HDL
Sibel Ertek
CURRENT VASCULAR PHARMACOLOGY (2018)
The role of lipoprotein (a) in chronic kidney disease
Jemma C. Hopewell et al.
JOURNAL OF LIPID RESEARCH (2018)
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Om P. Ganda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis JACC Macrophage in CVD Series (Part 2)
Kathryn J. Moore et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
Oxidized phospholipids and lipoprotein-associated phospholipase A(2) as important determinants of Lp(a) functionality and pathophysiological role
Alexandros D. Tselepis
JOURNAL OF BIOMEDICAL RESEARCH (2018)
Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study
Federica Fogacci et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
Mast cells in atherosclerotic cardiovascular disease - Activators and actions
Petri T. Kovanen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin
Nuntakorn Thongtang et al.
JOURNAL OF LIPID RESEARCH (2017)
Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity
Evangelia Zvintzou et al.
JOURNAL OF LIPID RESEARCH (2017)
Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity
Danish Saleheen et al.
NATURE (2017)
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
A. Michael Lincoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations
Farideh Razi et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2017)
Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Julia Schreml et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Jacqueline S. Dron et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Decline in Cardiovascular Mortality Possible Causes and Implications
George A. Mensah et al.
CIRCULATION RESEARCH (2017)
HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
Anish Bhatt et al.
CURRENT ATHEROSCLEROSIS REPORTS (2016)
Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component
Eva Herzog et al.
JOURNAL OF APPLIED TOXICOLOGY (2016)
Lipoprotein (a) measurements for clinical application
Santica M. Marcovina et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization
Eberhard Roeseler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Changes in mean serum lipids among adults in Germany: results from National Health Surveys 1997-99 and 2008-11
Julia Truthmann et al.
BMC PUBLIC HEALTH (2016)
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Florian Kronenberg
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
C. Michael Gibson et al.
CIRCULATION (2016)
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans
Fleur M. van der Valk et al.
CIRCULATION (2016)
Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
Changting Xiao et al.
DIABETES (2016)
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Andres Digenio et al.
DIABETES CARE (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Serum amyloid A impairs the antiinflammatory properties of HDL (vol 126, pg 796, 2016)
Chang Yeop Han et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein apheresis to treat elevated lipoprotein (a)
Elisa Waldmann et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
Borge G. Nordestgaard et al.
JOURNAL OF LIPID RESEARCH (2016)
Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?
Madhurima Das et al.
JOURNAL OF MOLECULAR BIOLOGY (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study
Anne Langsted et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
Rosie Z. Yu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study
G. Kees Hovingh et al.
AMERICAN HEART JOURNAL (2015)
HDL-cholesterol and cardiovascular disease: rethinking our approach
Hasan K. Siddiqi et al.
CURRENT OPINION IN CARDIOLOGY (2015)
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials
Susan Kuhnast et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia
R. Vongpromek et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis The Multi-Ethnic BioImage Study
Pradeep Natarajan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
Gregory G. Schwartz et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Apolipoprotein C-III: From Pathophysiology to Pharmacology
Giuseppe Danilo Norata et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
Pierluigi Tricoci et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Mendelian randomization of blood lipids for coronary heart disease
Michael V. Holmes et al.
EUROPEAN HEART JOURNAL (2015)
Amyloidogenic Propensity of a Natural Variant of Human Apolipoprotein A-I: Stability and Interaction with Ligands
Silvana A. Rosu et al.
PLOS ONE (2015)
Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant
Jonathan Dalla-Riva et al.
PLOS ONE (2015)
High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes
Anouar Hafiane et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Effects of Native and Myeloperoxidase-Modified Apolipoprotein A-I on Reverse Cholesterol Transport and Atherosclerosis in Mice
Bernd Hewing et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group
Michel R. Langlois et al.
ATHEROSCLEROSIS (2014)
Analysis of common and coding variants with cardiovascular disease in the diabetes heart study
Jeremy N. Adams et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation
Rodrigo Alonso
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Pia R. Kamstrup et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Triglycerides and cardiovascular disease
Borge G. Nordestgaard et al.
LANCET (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
Anand Rohatgi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
Daniel Keene et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
Robert A. Hegele et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The Influence of Innate and Adaptive Immune Responses on Atherosclerosis
Joseph L. Witztum et al.
Annual Review of Pathology-Mechanisms of Disease (2013)
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography
Maya S. Safarova et al.
ATHEROSCLEROSIS SUPPLEMENTS (2013)
Lipoprotein(a): resurrected by genetics
F. Kronenberg et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Thematic Review Series: High Density Lipoprotein Structure, Function, and Metabolism Unraveling the complexities of the HDL lipidome
Anatol Kontush et al.
JOURNAL OF LIPID RESEARCH (2013)
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
Pia R. Kamstrup et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Discovery and refinement of loci associated with lipid levels
Cristen J. Willer et al.
NATURE GENETICS (2013)
Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
Georgios Daniil et al.
PLOS ONE (2013)
Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study
Pia R. Kamstrup et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis
Pia R. Kamstrup et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Lipid-Related Markers and Cardiovascular Disease Prediction
Emanuele Di Angelantonio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils
Jitka Petrlova et al.
JOURNAL OF LIPID RESEARCH (2012)
Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Suguru Yamamoto et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
Robert S. Rosenson et al.
CLINICAL CHEMISTRY (2011)
Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2
Alexandra Kadl et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia
Kevin C. Maki et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL
Andreas K. Kateifides et al.
JOURNAL OF LIPID RESEARCH (2011)
Atherosclerosis: current pathogenesis and therapeutic options
Christian Weber et al.
NATURE MEDICINE (2011)
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I
Estelle Nobecourt et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men
Min-Jeong Shin et al.
ATHEROSCLEROSIS (2010)
Mechanisms of LDL oxidation
Hiroshi Yoshida et al.
CLINICA CHIMICA ACTA (2010)
CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer
Cameron R. Stewart et al.
NATURE IMMUNOLOGY (2010)
Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?
Roger K. Schindhelm et al.
CLINICAL CHEMISTRY (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory Particle
Arundhati Undurti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The LDL modification hypothesis of atherogenesis: an update
Daniel Steinberg
JOURNAL OF LIPID RESEARCH (2009)
Atorvastatin and fenofibrate have comparable effects on VLDL - Apolipoprotein C-III kinetics in men with the metabolic syndrome
Dick C. Chan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B
Arthur M. Baca et al.
CLINICAL CHEMISTRY (2008)
Glycation as an atherogenic modification of LDL
Nahla Younis et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome
Esther M. M. Ooi et al.
DIABETES CARE (2008)
Characterization and properties of preβ-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I
Phu T. Duong et al.
JOURNAL OF LIPID RESEARCH (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis
Christian A. Gleissner et al.
HYPERTENSION (2007)
Triglycerides and the risk of coronary heart disease - 10 158 incident cases among 262 525 participants in 29 Western prospective studies
Nadeem Sarwar et al.
CIRCULATION (2007)
Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis
Eiji Matsuura et al.
PROGRESS IN LIPID RESEARCH (2006)
Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells
Akio Kawakami et al.
CIRCULATION (2006)
What is so special about apolipoprotein AI in reverse cholesterol transport?
LK Curtiss et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
K Nagashima et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Myeloperoxidase: friend and foe
SJ Klebanoff
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL
K Okuhira et al.
JOURNAL OF LIPID RESEARCH (2004)
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
JR Nofer et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice
A Chroni et al.
BIOCHEMISTRY (2004)
Direct detection and quantification of transition metal ions in human atherosclerotic plaques: Evidence for the presence of elevated levels of iron and copper
N Stadler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages
VV Kunjathoor et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Structural and functional properties of apolipoprotein A-I mutants containing disulfide-linked cysteines at positions 124 or 232
SM Tian et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2002)
Myeloperoxidase, a leukocyte-derived vascular NO oxidase
JP Eiserich et al.
SCIENCE (2002)
Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration
MJ Graham et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Mechanisms for oxidizing low-density lipoprotein - Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis
JP Gaut et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2001)
Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages
T Shimaoka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
